@article{SchmidtWolfBrunner2016,
  author    = {Schmidt, Bernd and Wolf, Felix and Brunner, Heiko},
  title     = {Styrylsulfonates and -Sulfonamides through Pd-Catalysed Matsuda-Heck Reactions of Vinylsulfonic Acid Derivatives and Arenediazonium Salts},
  series = {European journal of organic chemistry},
  journal   = {European journal of organic chemistry},
  publisher = {Wiley-VCH},
  address   = {Weinheim},
  issn      = {1434-193X},
  doi       = {10.1002/ejoc.201600469},
  pages     = {2972 -- 2982},
  year      = {2016},
  abstract  = {Arene diazonium salts undergo Matsuda-Heck reactions with vinylsulfonates and -sulfonamides to give styrylsulfonic acid derivatives in high to excellent yields and with high to excellent selectivities. By quantifying the evolution of nitrogen over time in a gas-meter apparatus, the reactivities of ethylvinylsulfonate and the benchmark olefin methyl acrylate were compared for an electron-rich and an -deficient arene diazonium salt. Tertiary sulfonamides react in Matsuda-Heck couplings with high conversions, but require long reaction times, which prevents the determination of kinetic data through the measurement of nitrogen evolution. Secondary sulfonamides were found to be unreactive. From these results, the following order of reactivity could be deduced: H2C=CHCO2Me > H2C=CHSO2OEt > H2C=CHSO2N(Me)Bn >> H2C=CHSO2NHBn. Through the Matsuda-Heck coupling of 5-indolyldiazonium salt and a tertiary vinylsulfonamide, the synthesis of the C-5-substituted indole part of the antimigraine drug naratriptan was accomplished in high yield.},
  language  = {en}
}
@article{SchmidtKorbAbell2017,
  author    = {Schmidt, Marco F. and Korb, Oliver and Abell, Chris},
  title     = {Antagonists of the miRNA-Argonaute 2 Protein Complex},
  series = {Drug Target miRNA: Methods and Protocols},
  volume    = {1517},
  journal   = {Drug Target miRNA: Methods and Protocols},
  publisher = {Springer},
  address   = {New York},
  isbn      = {978-1-4939-6563-2},
  issn      = {1064-3745},
  doi       = {10.1007/978-1-4939-6563-2_17},
  pages     = {239 -- 249},
  year      = {2017},
  abstract  = {microRNAs (miRNAs) have been identified as high-value drug targets. A widely applied strategy in miRNA inhibition is the use of antisense agents. However, it has been shown that oligonucleotides are poorly cell permeable because of their complex chemical structure and due to their negatively charged backbone. Consequently, the general application of oligonucleotides in therapy is limited. Since miRNAs' functions are executed exclusively by the Argonaute 2 protein, we therefore describe a protocol for the design of a novel miRNA inhibitor class: antagonists of the miRNA-Argonaute 2 protein complex, so-called anti-miR-AGOs, that not only block the crucial binding site of the target miRNA but also bind to the protein's active site. Due to their lower molecular weight and, thus, more drug-like chemical structure, the novel inhibitor class may show better pharmacokinetic properties than reported oligonucleotide inhibitors, enabling them for potential therapeutic use.},
  language  = {en}
}